Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study.
Mohummad A RahmanJorunn BrekkeVictoria ArnesenMarianne H HannisdalAndrea G NavarroAndreas WahaLars HerfindalCecilie B RyghEirik BratlandPetter BrandalJudit HaaszLeif OltedalHrvoje MileticArvid LundervoldStein A LieDorota GoplenMartha ChekenyaPublished in: Immunity, inflammation and disease (2020)
Sequential BTZ + TMZ treatment is safe and promotes Th1-driven immunological responses in selected patients with improved clinical outcomes (Clinicaltrial.gov (NCT03643549)).